3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Plasma cell
1
Other neoplasm
1
NET
1
Myeloid
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Myelodysplastic Syndromes
750
Leukemia, Myeloid, Acute
635
Leukemia
476
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
470
Precursor Cell Lymphoblastic Leukemia-Lymphoma
409
Myeloproliferative Disorders
339
Lymphoma, Non-Hodgkin
271
Leukemia, Myelomonocytic, Chronic
270
Leukemia, Lymphocytic, Chronic, B-Cell
264
Multiple Myeloma
259
Hodgkin Disease
249
Primary Myelofibrosis
230
Leukemia, Myeloid, Chronic-Phase
217
Lymphoma
203
Blast Crisis
195
Leukemia, Myeloid, Accelerated Phase
182
Lymphoma, Mantle-Cell
168
Lymphoma, Follicular
168
Burkitt Lymphoma
166
Lymphoma, Large B-Cell, Diffuse
162
Lymphoma, B-Cell, Marginal Zone
151
Congenital Abnormalities
148
Polycythemia Vera
144
Lymphoma, Large-Cell, Immunoblastic
141
Anemia, Refractory, with Excess of Blasts
131
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
128
Myelodysplastic-Myeloproliferative Diseases
126
Neoplasms, Plasma Cell
117
Thrombocythemia, Essential
114
Lymphoma, T-Cell, Cutaneous
99
Interventions
nilotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplastic Processes
×
Myeloid
×
Clear all
NCT01844765
2021-04-22
DIALOG
Novartis
Phase 2
Completed
59 enrolled
33 charts
1 FDA